Treatment of Wegener's Granulomatosis With Cyclophosphamide - Tabular View

Home

Study Topics

Glossary


	Full Text View


	Tabular View


	Contacts and Locations


	No Study Results Posted


	Related Studies

Treatment of Wegener's Granulomatosis With Cyclophosphamide

This study has been completed.

Study NCT00001155. Last updated on March 3, 2008. Information provided by National Institutes of Health Clinical Center (CC)

This Tabular View shows the required WHO registration data elements as marked by ^†

Descriptive Information Fields
Brief Title ^†	Treatment of Wegener's Granulomatosis With Cyclophosphamide
Official Title ^†	Treatment of Wegener's Granulomatosis With Cyclophosphamide
Brief Summary	The purpose of this protocol is to continue to treat patients with Wegener's granulomatosis who have already entered the study, and to treat new patients. The investigators will attempt to correlate the clinical response with specific immunosuppressive effects of drug administration. The investigators are accumulating data on the optimal duration and side effects of therapy.
Detailed Description	The purpose of the protocol is to continue to treat patients with Wegener's granulomatosis who have already entered the study, and to treat new patients. The investigators will attempt to correlate the clinical response with specific immunosuppressive effects of drug administration. The investigators are accumulating data on the optimal duration and side effects of therapy. Age Range: greater than 1 year
Study Phase	Phase II
Study Type ^†	Interventional
Study Design ^†	Treatment, Safety/Efficacy Study
Primary Outcome Measure ^†
Secondary Outcome Measure ^†
Condition ^†	Vasculitis Wegener's Granulomatosis
Intervention ^†	Drug: cyclophosphamide
MEDLINE PMIDs	8602705, 1739240
Links

Recruitment Information Fields
Recruitment Status ^†	Completed
Enrollment ^†	200
Start Date ^†	February 1976
Completion Date	February 2002
Eligibility Criteria ^†	Patients greater than 1 year of age with the clinical and pathological diagnosis of WG whose illness presents a risk of permanent disability or death. Examples of processes that impart risk of permanent disability or death include: peripheral and central nervous system disease, cardiac involvement, glomerulonephritis, and vascular comprise of gastrointestinal organs. No women who are pregnant or intend to become pregnant. No patients who have known malignancies. Patients must be HIV negative.
Gender	Both
Ages
Accepts Healthy Volunteers	No
Contacts ^††
Location Countries ^†	United States

Administrative Information Fields
NCT ID ^†	NCT00001155
Organization ID	760042
Secondary IDs ^††	76-I-0042
Study Sponsor ^†	National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators ^††
Investigators ^†
Information Provided By	National Institutes of Health Clinical Center (CC)
Verification Date	February 2002
First Received Date ^†	November 3, 1999
Last Updated Date	March 3, 2008

^† Required WHO trial registration data element.
^†† WHO trial registration data element that is required only if it exists.